Brawn Biotech Board Approves Q1 FY27 Unaudited Financial Results

Brawn Biotech Ltd announced that its Board of Directors, following recommendations from the Audit Committee, has approved the unaudited financial results for the quarter ended June 30, 2026. The board also recommended the appointment of M/s GD S M and Co as Statutory Auditors for a five-year term. Additionally, the company will convene its 41st Annual General Meeting on September 29, 2026, via VC/OAVM, and has approved the Board's Report for the financial year ended March 31, 2026. The meeting was held on August 13, 2026.